Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HTR1F | P30939 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.47 |
| ▸ | WNT1 | P04628 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072590 | 0.86 | RAB9A (0.54) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2072611 | 0.84 | SMN1; SMN2 (0.73) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2075678 | 0.84 | MAPK1 (0.53) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2075547 | 0.82 | RAB9A (0.50) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2075244 | 0.81 | RAB9A (0.74) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2076140 | 0.78 | OGA (0.47) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2075468 | 0.77 | EGFR (0.48) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2073745 | 0.77 | SMN1; SMN2 (0.49) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2073083 | 0.76 | SMN1; SMN2 (0.43) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 | |
| SCHEMBL2072595 | 0.76 | EGFR (0.53) | RAB9ASMN1; SMN2ALDH1A1EGFRERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| CN-101448820-A | Piperidinyl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | RAB9A 1046/4885SMN1; SMN2 4105/4885ALDH1A1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.